KalVista Pharmaceuticals (KALV) Operating Expenses (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Operating Expenses of $60.4 million in Q3 2025, up 9.82% quarter-over-quarter from $55.0 million in Q2 2025, and up 36.68% year-over-year from $44.2 million in Q3 2024.
KalVista Pharmaceuticals' Operating Expenses history runs 12 years deep, the most recent figure standing at $60.4 million for Q3 2025.
- In Q3 2025, Operating Expenses rose 36.68% year-over-year to $60.4 million; the TTM figure through Jul 2025 stood at $161.3 million (up 3.67% YoY), while the FY2025 annual figure was $188.0 million, up 33.86% from the prior year.
- Operating Expenses came in at $60.4 million for Q3 2025 at KalVista Pharmaceuticals, up from $55.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $60.4 million in Q3 2025 to a low of $12.7 million in Q1 2021.
- A 5-year average of $32.5 million and a median of $28.0 million in 2023 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses declined 11.5% in 2021 and soared 110.82% in 2022, its largest moves.
- KalVista Pharmaceuticals' Operating Expenses stood at $23.6 million in 2021, then rose by 9.66% to $25.9 million in 2022, then grew by 14.92% to $29.7 million in 2023, then soared by 54.01% to $45.8 million in 2024, then jumped by 31.92% to $60.4 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $60.4 million, $55.0 million, and $45.8 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 60.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 60.44 Mn |
| Apr 30, 2025 | 55.03 Mn |
| Oct 31, 2024 | 45.81 Mn |
| Jul 31, 2024 | 44.22 Mn |
| Apr 30, 2024 | 48.46 Mn |
| Jan 31, 2024 | 33.15 Mn |
| Oct 31, 2023 | 29.75 Mn |
| Jul 31, 2023 | 29.09 Mn |
| Apr 30, 2023 | 31.73 Mn |
| Jan 31, 2023 | 26.95 Mn |
| Oct 31, 2022 | 25.88 Mn |
| Jul 31, 2022 | 26.32 Mn |
| Apr 30, 2022 | 26.81 Mn |
| Jan 31, 2022 | 26.68 Mn |
| Oct 31, 2021 | 23.60 Mn |
| Jul 31, 2021 | 19.52 Mn |
| Apr 30, 2021 | 18.04 Mn |
| Jan 31, 2021 | 12.66 Mn |
| Oct 31, 2020 | 12.78 Mn |
| Jul 31, 2020 | 14.44 Mn |
| Apr 30, 2020 | 12.78 Mn |
| Jan 31, 2020 | 14.30 Mn |
| Oct 31, 2019 | 13.21 Mn |
| Jul 31, 2019 | 12.93 Mn |
| Apr 30, 2019 | 14.19 Mn |
| Jan 31, 2019 | 10.55 Mn |
| Oct 31, 2018 | 10.49 Mn |
| Jul 31, 2018 | 10.73 Mn |
| Apr 30, 2018 | 7.81 Mn |
| Jan 31, 2018 | 6.68 Mn |
| Oct 31, 2017 | 7.06 Mn |
| Jul 31, 2017 | 5.55 Mn |
| Apr 30, 2017 | 5.20 Mn |
| Jan 31, 2017 | 8.37 Mn |
| Oct 31, 2016 | 4.22 Mn |
| Jul 31, 2016 | 6.10 Mn |
| Mar 31, 2016 | 6.54 Mn |
| Dec 31, 2015 | 5.58 Mn |
| Sep 30, 2015 | 4.91 Mn |
| Jun 30, 2015 | 5.67 Mn |
| Mar 31, 2015 | 4.91 Mn |
| Dec 31, 2014 | 3.83 Mn |
| Sep 30, 2014 | 3.58 Mn |
| Jun 30, 2014 | 2.44 Mn |
| Mar 31, 2014 | 1.86 Mn |